Targeting EPHB2/ABL1 restores antitumor immunity in preclinical models of ependymoma

What is it about?

Ependymoma is a rare pediatric brain cancer that responds poorly to current treatments. Our research identified an FDA-approved drug (Dasatinib) that inhibits a key signaling pathway involved in tumor growth, effectively destroying cancer cells while also reprogramming the immune system to target diseased tissue. Remarkably, this drug eliminates brain tumors in a mouse model of ependymoma without causing additional side effects. Furthermore, Dasatinib not only cures the mice but also provides long-term protection against tumor recurrence.

Featured Image